Narlaprevir

Narlaprevir is an experimental drug that was developed for the treatment of Hepatitis C. It is a protease inhibitor, specifically targeting the NS3/4A protease of the Hepatitis C virus.

History

Narlaprevir was developed by Schering-Plough, a pharmaceutical company that was later acquired by Merck & Co.. The drug was initially tested in clinical trials as a potential treatment for Hepatitis C, but development was discontinued in 2013.

Mechanism of Action

As a protease inhibitor, Narlaprevir works by blocking the action of the NS3/4A protease, an enzyme that the Hepatitis C virus needs to replicate. By inhibiting this enzyme, Narlaprevir prevents the virus from multiplying and spreading in the body.

Clinical Trials

Narlaprevir was tested in several clinical trials. In a Phase II trial, it was found to be effective in reducing viral load in patients with Hepatitis C. However, the drug was associated with significant side effects, including rash and anemia.

In a Phase III trial, Narlaprevir was tested in combination with other antiviral drugs. The results of this trial were promising, but development of the drug was discontinued before it could be approved for use.

Discontinuation

The development of Narlaprevir was discontinued in 2013. The reasons for this decision have not been publicly disclosed, but it is likely that the decision was influenced by the emergence of newer, more effective treatments for Hepatitis C.

See Also

• Hepatitis C
• Protease inhibitor
• Clinical trial
• Schering-Plough
• Merck & Co.

Narlaprevir Resources
Latest articles Most recent articles Ongoing trials	Wikipedia